R&D Innovation Accelerator

Shanghai Children's Hospital and GenSci Ink Strategic Cooperation Agreement

Recently, Shanghai Children's Hospital has signed a strategic cooperation agreement with Changchun GeneScience Pharmaceutical Co., Ltd. (hereinafter referred to as GenSci). Under the agreement, the two sides will collaboratively set up a research and development (R&D) center. This initiative is designed to facilitate the exchange of scientific research and to hasten the translation of scientific and technological breakthroughs into commercial applications. Mr. Lu Bing, Director of Shanghai Children's Hospital, and Mr. Jin Lei, General Manager of GenSci, signed the agreement.

Shanghai Children's Hospital features specialized advantages in various diseases such as pediatric respiratory diseases, pediatric infectious diseases, pediatric digestive infections, pediatric endocrinology, and urinary system, as well as the domestic leading position in the treatment and research of pediatric respiratory diseases and inflammatory bowel diseases.

The partnership is strategically targeted at fulfilling the unmet clinical requirements of pediatric patients, leveraging the pivotal projects of the hospital's central departments. With a shared vision, the two entities will work closely in areas such as innovative pharmaceuticals, novel formulations, cutting-edge medical devices, and specialized medical nutrition to bring a healthier life for children.

Mr. Jin Lei underscored in his speech, "GenSci is at the forefront of a strategic evolution, transitioning from a specialized endocrinology focus to a broader spectrum of therapeutic areas. We are intensifying our commitment to pediatric and women's health, extending our services to encompass the entire life-cycle of children and a holistic approach to women's health management. "

GenSci's transformation is propelled by its robust suite of advanced technology platforms. The company has established five major platforms, including pivotal biopharmaceutical technologies such as monoclonal, bispecific, and multi-specific antibodies; Technology Platform for Special Formulation Development; Platform for Medical Devices, and Artificial Intelligence Platform that spans the entire drug development cycle. These platforms have bolstered GenSci with the capacity for comprehensive innovation across the healthcare lifecycle, from screening and diagnosis to prevention, treatment, intervention, and rehabilitation.

“As healthcare needs become more specialized, GenSci and our hospital partners must work together to streamline clinical diagnostics and treatment," said Jin Lei. "Our combined expertise and technology will enhance patient care and contribute to the broader public health.”

"The signing ceremony marks a significant step forward in our collaboration," remarked Mr. Lu Bing. "By integrating with academic and corporate sectors, we are committed to enhancing the hospital's capabilities, amplifying our research impact, and cultivating the talent vital for excellence in healthcare development."

He further highlighted, "Leveraging GenSci's strengths in AI Drug Design, medical devices, and innovative formulations, we are poised to advance pediatric pharmaceutical research and application. This synergy will hopefully elevate the healthcare experience and improve the overall well-being of our patients.